Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.
about
Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses.Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in miceInduction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculationIn vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunityEnhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 GIncorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells.Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.Expression and characterization of virus-like particles containing rubella virus structural proteins.A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines.
P2860
Q33643167-5B2E485E-6D5E-4A9D-B038-A12952845672Q33717736-90C44073-0E39-4175-8684-5882ACEB22C3Q33788701-0194F161-9802-48D7-99DB-434CAC27FFD1Q33806244-7A9B04AF-2FBA-4127-B281-895A7B026BB3Q34342982-B5208E07-47F0-4470-8663-89FAF08A61C0Q35840819-F7171B81-C0E3-4682-BD77-1D427126595BQ36628522-26178B6D-F792-427D-AD40-6882D0820BC2Q36659320-0ADCF545-108B-4C3D-A2EC-1224FAF3278AQ37834097-5A539B59-1C0C-4309-AB4D-B580828F75D0Q39698363-DE7C0CD6-FAA8-4CC2-B0A4-2B7F6107DC03Q40012120-6D32041E-C0EE-485E-9A44-21A61761648FQ40041208-00F58A75-D8EF-4DC0-A23A-F114483F91E1Q40041619-52FB6757-7E6E-4A79-9A55-ACA1B1E12199
P2860
Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Hybrid human immunodeficiency ...... responses by a Gag:V3 fusion.
@ast
Hybrid human immunodeficiency ...... responses by a Gag:V3 fusion.
@en
type
label
Hybrid human immunodeficiency ...... responses by a Gag:V3 fusion.
@ast
Hybrid human immunodeficiency ...... responses by a Gag:V3 fusion.
@en
prefLabel
Hybrid human immunodeficiency ...... responses by a Gag:V3 fusion.
@ast
Hybrid human immunodeficiency ...... responses by a Gag:V3 fusion.
@en
P2093
P2860
P1433
P1476
Hybrid human immunodeficiency ...... responses by a Gag:V3 fusion.
@en
P2093
Griffiths JC
Kingsman AJ
P2860
P304
P407
P577
1993-06-01T00:00:00Z